ArticleAnnals of surgical oncology2026
Evolution of Axillary Surgical Management of Patients with Occult Breast Cancer with Axillary Metastasis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs axillary surgery de-escalates and neoadjuvant systemic therapy (NST) improves, we sought to evaluate changes in axillary surgery and impact on overall survival (OS) in occult breast cancer with axillary metastasis. PATIENTS AND
methodsUsing the National Cancer Database, we identified patients with cT0N+ breast cancer who underwent axillary surgery between 2012 and 2023. Lymph node surgery trends were assessed using Cochran-Armitage trends tests and the Kaplan-Meier method evaluated OS.
resultsWe identified 1817 patients with cT0N+ breast cancer (75% had surgery first and 25% received NST). NST use significantly increased over time. Patients undergoing upfront surgery primarily underwent ALND (94% ALND, 6% SLN only); however, ALND decreased from 96 to 82% (2012-2023), p < 0.001. Three-year OS was similar between SLN and ALND in this cohort (96% versus 93%, p = 0.12). In patients who received NST, ALND rate was lower and had a greater decrease from 97 to 70% (2012-2023), p < 0.001, especially 2017 onwards. Of ypN0 patients, 26.0% underwent SLN only with highest rates in the most recent year (2023: 44.4%), whereas 9.6% of patients with ypN+ had SLN only. OS was similar between SLN only and ALND for patients with ypN0 disease (3 year Kaplan-Meier estimates 100% versus 96%, p = 0.77) as well as ypN+ disease (93 versus 91%, p = 0.43).
conclusionsFor patients with occult breast cancer with axillary metastases, the extent of axillary surgery is deescalating, with the greatest decrease in those receiving NST. Early survival data suggests a lack of survival benefit with ALND compared with SLN surgery with appropriate patient selection.
Indexed as
Identifiers
42467152What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.